Open AccessSodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Author(s) -
Elisabetta Patorno,
Phyo T. Htoo,
Robert J. Glynn,
Sebastian Schneeweiß,
Deborah J. Wexler,
Lily G. Bessette,
Kristyn Chin,
Brendan M. Everett,
Seoyoung Kim
Publication year - 2021
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m21-0893
Subject(s) - medicine , hazard ratio , myocardial infarction , type 2 diabetes , stroke (engine) , diabetes mellitus , population , placebo , heart failure , glucagon like peptide 1 receptor , endocrinology , confidence interval , receptor , mechanical engineering , alternative medicine , environmental health , pathology , engineering , agonist
Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-controlled trials of patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).